

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 廣州藥業股份有限公司

**Guangzhou Pharmaceutical Company Limited**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## ANNOUNCEMENT

Guangzhou Pharmaceutical Company Limited (the “Company”) has been informed that Guangzhou Pharmaceutical Holdings Limited (“GPHL”), the controlling shareholder of the Company, received a notice calling for responses to legal proceedings (the “Notice”) **【(2012)-Zhongmintezi No.7160】** from the Beijing No.1 Intermediate People’s Court\* (北京市第一中級人民法院) (the “Court”) of the People’s Republic of China (the “PRC”) on 1 June 2012. According to the Notice, the Court has accepted the application made by Hung To (Holdings) Company for revoking the arbitration ruling (the “Arbitration Ruling”) made by the China International Economic and Trade Arbitration Commission on 9 May 2012 (for details, please refer to the announcement published by the Company dated 11 May 2012).

GPHL has sought legal advice in relation to the Arbitration Ruling. In accordance with the relevant provisions in the PRC Arbitration Law\* (仲裁法), the rulings of arbitration shall be final and binding once the ruling is made, and the Arbitration Ruling is legally effective at the date of its making. The party who refuses to accept the Arbitration Ruling can apply for revoking the same through the court. Unless and until the Arbitration Ruling is revoked by the Court, the Arbitration Ruling is effective and final and its legality would not be affected.

The board of the directors of the Company (the “Board”) confirms that, other than the Notice, it is not in possession of information which the Company is required to disclose under the listing rules of the Shanghai Stock Exchange or Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Hong Kong Listing Rules”), nor is the Board aware of any information which may have any significant impact on the Company’s share price and is therefore discloseable under the listing rules of the Shanghai Stock Exchange or Hong Kong Listing Rules.

The Company’s designated media for publication of its information includes Shanghai Securities News, Securities Times, the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to pay attention to investment risks.

This announcement is made pursuant to Rule 13.09(2) of the Hong Kong Listing Rules.

The Board of  
**Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 4 June 2012

*As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.*

\* For identification only